Innovent Biologics Stock price
Is Innovent Biologics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.
Key metrics
Innovent Biologics Stock Analysis
Analyst Opinions
38 Analysts have issued a Innovent Biologics forecast:
Analyst Opinions
38 Analysts have issued a Innovent Biologics forecast:
Don't miss a Thing! We will send you all news about Innovent Biologics directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Innovent Biologics Stock News
Company Profile
Innovent Biologics, Inc. is a biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases. The company is headquartered in Suzhou, Jiangsu and currently employs 5,659 full-time employees. The company went IPO on 2018-10-31. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The firm mainly operates in the domestic and overseas markets.
| Head office | China |
| CEO | Dr. Yu |
| Employees | 7,502 |
| Website | www.innoventbio.com |


